Effect of the UGT2B15 genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers

Clinical Pharmacology and Therapeutics

Volumn 77, Issue 6, 2005, Pages 486-494

  Chung, Jae Yong ^a   Cho, Joo Youn ^a   Yu, Kyung Sang ^a   Kim, Jung Ryul ^a   Jung, Hye Ryung ^a   Lim, Kyoung Soo ^a   Jang, In Jin ^a   Shin, Sang Goo ^a  

^a Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

LORAZEPAM; RIFAMPICIN; VALPROIC ACID;

ADULT; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; GLUCURONIDATION; HUMAN; LIQUID CHROMATOGRAPHY; MALE; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PSYCHOMOTOR PERFORMANCE; TANDEM MASS SPECTROMETRY; VISUAL ANALOG SCALE;

ADULT; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; GENOTYPE; GLUCURONOSYLTRANSFERASE; HUMANS; HYPNOTICS AND SEDATIVES; INFUSIONS, INTRAVENOUS; LORAZEPAM; MALE; POLYMORPHISM, GENETIC; RIFAMPIN; VALPROIC ACID;

EID: 20444500240     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2005.02.006     Document Type: Article

References (25)

1. J.O. Miners, P.I. Mackenzie Drug glucuronidation in humans Pharmacol Ther 51 1991 347 369
2. C. Guillemette Pharmacogenomics of human UDP-glucuronosyltransferase enzymes Pharmacogenomics J 3 2003 136 158
3. M.D. Green, E.M. Oturu, T.R. Tephly Stable expression of a human liver UDP-glucuronosyltransferase (UGT2B15) with activity toward steroid and xenobiotic substrates Drug Metab Dispos 22 1994 799 805
4. M. Riedy, J.Y. Wang, A.P. Miller, A. Buckler, J. Hall, M. Guida Genomic organization of the UGT2b gene cluster on human chromosome 4q13 Pharmacogenetics 10 2000 251 260
5. J.W. Lampe, J. Bigler, A.C. Bush, J.D. Potter Prevalence of polymorphisms in the human UDP-glucuronosyltransferase 2B family UGT2B4 (D458E), T2B7 (H268Y) and UGT2B15 (D85Y) Cancer Epidemiol Biomarkers Prev 9 2000 329 333
6. M.H. Court, S.X. Duan, C. Guillemette, K. Journault, S. Krishnaswamy, L.V. Moltke Stereoselective conjugation of oxazepam by human UDP-glucuronosyltransferase (UGTs) S-oxazepam is glucuronidated by UGT2B15, while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9 Drug Metab Dispos 30 2002 1257 1265
7. M. Patel, B.K. Tang, W. Kalow Interindividual variability in the glucuronidation of (S) oxazepam contrasted with that of (R) oxazepam Pharmacogenetics 5 1995 287 297
8. M.H. Court, Q. Hao, S. Krishnaswamy, T. Bekaii-Saab, A. Alrohaimi, L.L. Moltke UDP-glucuronosyltransferase (UGT) 2B15 pharmacogenetics UGT2B15 D85Y genotype and gender are major determinants of oxazepam glucuronidation by human liver J Pharmacol Exp Ther 310 2004 656 665
9. C. Dollery Therapeutic drugs 2nd ed. 1999 Churchill Livingstone Edinburgh (UK) O38 O41
10. M.H. Court, Q. Hao, L.M. Hesse, A. Alrohaimi, S. Krishnaswamy Influence of UGT2B15 genetic polymorphisms on glucuronidation of oxazepam, lorazepam, 5-hydroxyrofecoxib and E-4-hydroxytamoxifen [abstract] Clin Exp Pharmacol Physiol 31 Suppl 1 2004 A135
11. E.E. Samara, R.G. Granneman, G.F. Witt, J.H. Cavanaugh Effect of valproate on the pharmacokinetics and pharmacodynamics of lorazepam J Clin Pharmacol 37 1997 442 450
12. K. Dilger, U. Hofmann, U. Klotz Enzyme induction in the elderly effect of rifampin on the pharmacokinetics and pharmacodynamics of propafenone Clin Pharmacol Ther 67 2000 512 520
13. S.N. de Wildt, G.L. Kearns, J.S. Leeder, J.N. van den Anker Glucuronidation in humans. Pharmacogenetic and developmental aspects Clin Pharmacokinet 36 1999 439 452
14. U. Fuhr Introduction of drug metabolizing enzymes pharmacokinetic and toxicological consequences in humans Clin Pharmacokinet 38 2000 493 504
15. R.G. Tirona, B.F. Leake, A.W. Wolkoff, R.B. Kim Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation J Pharmacol Exp Ther 304 2003 223 228
16. H. Derendorf, G. Hochhaus Handbook of pharmacokinetic/pharmacodynamic correlation 1995 CRC Boca Raton 171 182
17. A. Patat, M.C. Perault, B. Vandel, N. Ulliac, I. Zieleniuk, P. Rosenzweig Lack of interaction between a new antihistamine, mizolastine, and lorazepam on psychomotor performance and memory in healthy volunteers Br J Clin Pharmacol 39 1995 31 38
18. E.E. Samara, R.G. Granneman, G.F. Witt, J.H. Cavanaugh Effect of valproate on the pharmacokinetics and pharmacodynamics of lorazepam J Clin Pharmacol 37 1997 442 450
19. B.T. Ethell, G.D. Anderson, B. Burchell The effect of valproate on drug and steroid glucuronidation by expressed human UDP-glucuronosyltransferases Biochem Pharmacol 65 2003 1441 1449
20. S.A. Lee, J.K. Lee, K. Heo Coma probably induced by lorazepam-valproate interaction Seizure 11 2002 124 125
21. J. Park, L. Chen, K. Shade, P. Lazarus, J. Seigne, S. Patterson Asp85tyr polymorphism in the udp-glucuronosyltransferase (UGT) 2B15 gene and the risk of prostate cancer J Urol 171 Pt 1 2004 2484 2488
22. T. Hajdinjak, B. Zagradisnik Prostate cancer and polymorphism D85Y in gene for dihydrotestosterone degrading enzyme UGT2B15 frequency of DD homozygotes increases with Gleason score Prostate 59 2004 436 439
23. N. Iwata, D.S. Cowley, M. Radel, P.P. Roy-Byrne, D. Goldman Relationship between a GABAAα6 Pro385Ser substitution and benzodiazepine sensitivity Am J Psychiatry 156 1999 1447 1449
24. D.N. Bowser, D.A. Wagner, C. Czajkowski, B.A. Cromer, M.W. Parker, R.H. Wallace Altered kinetics and benzodiazepine sensitivity of a GABAA receptor subunit mutation [gamma 2(R43Q)] found in human epilepsy Proc Natl Acad Sci U S A 99 2002 15170 15175
25. H. Kanazawa, Y. Kunito, Y. Matsushima, S. Okubo, F. Mashige Stereospecific analysis of lorazepam in plasma by chiral column chromatography with a circular dichroism-based detector J Chromatogr A 871 2000 181 188